Office: South San Francisco, CA

Executive Assistant:
Suzy DeVito
(650) 238-5056

Dennis Henner, PhD
Chief Scientific Advisor

Dennis Henner, PhD, is the firm's Chief Scientific Advisor, prior to this he served as Managing Director of Clarus for 12 years beginning in 2005 with the firm’s inception. Prior to Clarus, Dr. Henner was a General Partner at MPM Capital, a healthcare venture capital firm. He has over 30 years of direct industry and investment experience within the healthcare sector.

From 1981 to 2001, Dr. Henner was an executive at Genentech where he held various positions including Senior Vice President of Research, and was a member of Genentech's executive committee.

Dr. Henner received his PhD from the Department of Microbiology at the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation.

Dr. Henner is a member of the Board of Trustees of Reed College.


Current Board Seats

Previous Board Seats

Aerie (NASDAQ: AERI)

Cellerant

Ceregene Inc.(acquired by Sangamo BioSciences)

Comentis

Ferrokin (acquired by Shire)

Kalobios

Pelikan Technologies

Proacta

Rinat (acquired by Pfizer)

Rigel (NASDAQ:RIGL)

SARcode (acquired by Shire)

Synergia

Tercica (acquired by Ipsen)

Clarus Board Seats

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Public
Team: Dennis Henner
Emmett Cunningham

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI)

Aerie Pharmaceuticals is a privately held, clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma. Aerie’s internal research and development engine has generated an innovative glaucoma pipeline. In addition to AR-12286, the Company’s Rho-kinase (ROCK) inhibitor, the pipeline includes AR-13165, a novel product candidate with a dual mechanism of action that represents the first of a new proprietary class of glaucoma drugs. AR-13165 is currently in preclinical, IND-enabling studies.

Aerie Website

Fund: Clarus Lifesciences III, L.P.
Sector: Biotechnology
Type: Private
Team: William Young
Dennis Henner
Emmett Cunningham

Annexon Biosciences

Annexon is developing novel antibody therapeutics for neurodegenerative and autoimmune disorders. Annexon’s most advanced program targets Huntington’s disease

Annexon Website

Fund: Clarus Lifesciences I, L.P.
Sector: Biotechnology
Type: Public
Team: Nicholas J. Simon
Dennis Henner
Emmett Cunningham

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR)

Avanir Pharmaceuticals (Nasdaq:AVNR) is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. Avanir’s products and product candidates address therapeutic markets that include central nervous system disorders, inflammation, and infectious disease. Zenvia™ is Avanir's lead product candidate for the treatment of pseudobulbar affect (PBA), also known as involuntary emotional expression disorder (IEED).

Avanir Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Defined Exit
Team: Robert W. Liptak
Kurt C. Wheeler
Dennis Henner
Emmett Cunningham
Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Private
Team: Dennis Henner

Cleave Biosciences

Cleave Biosciences is an early stage oncology therapeutics company focused on novel targets in cellular protein homeostasis pathways. Controlled largely by two distinct systems – the ubiquitin proteasome system and the autophagy system, these pathways are utilized by cancer cells for their growth and survival. 

The company secured a $42M Series A investment in October 2011.

Cleave Website

Fund: Clarus Lifesciences I, L.P.
Sector: Biotechnology
Type: Private
Team: Nicholas J. Simon
Dennis Henner
Michele Park

CoMentis, Inc.

CoMentis, Inc. is engaged in the discovery and development of small-molecule drugs to treat neurovascular disease indications, such as Alzheimer’s disease, AMD and cognitive disorders.  The company has two fundamental technology platforms:  (i) beta-secretase inhibitors for the treatment of Alzheimer’s disease; and (ii) nACh receptor agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders.

CoMentis Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Private
Team: Dennis Henner
Emmett Cunningham

FerroKin Biosciences, Inc. acquired by Shire Plc. in March 2012

FerroKin Biosciences Inc., a San Carlos, Calif.-based company, is developing an iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. Clarus Ventures has co-invested with Burrill & Co. and Celgene Inc.

Fund: Clarus Lifesciences III, L.P.
Sector: Biotechnology
Type: Private
Team: Dennis Henner

Forty Seven, Inc.

With a passion for pioneering breakthrough solutions, Forty Seven, Inc. is committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.

Forty Seven Website

Fund: Clarus Lifesciences III, L.P.
Sector: Biotechnology
Type: Private
Team: Dennis Henner

Imago BioSciences

Imago BioSciences is a San Francisco-based clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians. The company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases. Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives.

Imago BioSciences Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Public
Team: Scott Requadt
Nicholas J. Simon
Dennis Henner

Intercept Pharmaceuticals (NASDAQ: ICPT)

Intercept is focused on the development and commercialization of novel, small molecule therapeutics to treat chronic liver disease by leveraging its expertise in bile acid chemistry.  Its lead candidate, obaticholic acid (OCA), is an FXR agonist that is currently in pivotal trials for primary biliary cirrhosis (PBC), a chronic autoimmune liver disease.  OCA has received orphan designation for PBC in both the US and Europe.  OCA is also being evaluated in an NIH-sponsored trial for non-alcoholic steatohepatitis (NASH).

Intercept Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Private
Team: Nicholas J. Simon
Dennis Henner

Lycera Corporation

Lycera is an early stage biotechnology company developing first in class small molecule drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease.  Lycera’s pipeline includes proprietary small molecules against two novel targets, a mitochondrial molecule that  is central to lymphocyte bioenergetics and a nuclear hormone receptor that modulates the Th17 pathway.  Lycera’s small molecule drugs have the potential for best in class oral efficacy without the adverse effects of current immunosuppressive agents.

Lycera Website

Fund: Clarus Lifesciences I, L.P.
Sector: Biotechnology
Type: Private
Team: Dennis Henner
Emmett Cunningham

SARcode, Inc. acquired by Shire in March 2013

SARcode is a private, San Francisco based company focused on the development of small molecule LFA-1 inhibitors to treat inflammatory diseases. In December, 2006 SARcode secured $25 million in a financing co-led by Clarus Ventures and Alta Partners.

SARcode Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Defined Exit
Team: Robert W. Liptak
Scott Requadt
Kurt C. Wheeler
Dennis Henner
Michele Park
Emmett Cunningham

SFJ Pharmaceuticals, Inc.

SFJ Pharmaceuticals (SanFrancisco/Japan) serves as a clinical development specialty pharma company with a focus on obtaining product approval in Japan. Targeted candidates for development in Japan are low risk compounds that are already approved or have a high likelihood of approval in the US with projected Japan annual sales in excess of $100M. To date, SFJ has entered definitive agreements with two major global pharma companies to fund Phase 3 trials for oncology assets. Pre-determined milestone payments to SFJ shall be received on approval of the asset in pre-specified countries.

SFJ Pharmaceuticals Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Public
Team: Dennis Henner

TetraLogic Pharmaceuticals, Inc. (NASDAQ: TLOG)

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company founded on a mechanism that has the potential to promote apoptosis, or programmed cell death, in cancer cells. Cancer cells are often resistant to apoptosis and Tetralogic’s lead molecule, a Smac-mimetic, may abrogate that resistance. The Smac-mimetic is currently in clinical trials for the treatment of cancer.

TetraLogic Website